このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Soligenix 将来の成長

Future 基準チェック /26

Soligenixの収益は年間1.5%で減少すると予測されていますが、年間収益は年間75.8%で増加すると予想されています。EPS は年間16.7%で増加すると予想されています。

主要情報

-1.5%

収益成長率

16.7%

EPS成長率

Biotechs 収益成長	31.2%
収益成長率	75.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	24 Apr 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:DOA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	17	-14	N/A	N/A	1
12/31/2024	9	-15	N/A	N/A	2
12/31/2023	1	-16	N/A	N/A	2
12/31/2022	1	-14	-13	-13	N/A
9/30/2022	1	-15	-12	-12	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-15	-11	-11	N/A
12/31/2021	1	-13	-12	-12	N/A
9/30/2021	1	-13	-13	-13	N/A
6/30/2021	1	-12	-13	-13	N/A
3/31/2021	2	-12	-13	-13	N/A
12/31/2020	2	-18	-11	-11	N/A
9/30/2020	3	-15	-10	-10	N/A
6/30/2020	3	-16	-9	-9	N/A
3/31/2020	4	-15	-8	-8	N/A
12/31/2019	5	-9	-8	-8	N/A
9/30/2019	5	-10	-8	-8	N/A
6/30/2019	5	-9	-6	-6	N/A
3/31/2019	5	-8	-8	-8	N/A
12/31/2018	5	-9	-7	-7	N/A
9/30/2018	6	-8	-7	-7	N/A
6/30/2018	6	-7	-7	-7	N/A
3/31/2018	5	-8	-6	-6	N/A
12/31/2017	5	-7	-7	-7	N/A
9/30/2017	6	-5	-6	-6	N/A
6/30/2017	7	-6	-6	-6	N/A
3/31/2017	9	-4	-6	-6	N/A
12/31/2016	10	-3	-5	-5	N/A
9/30/2016	12	-5	N/A	-5	N/A
6/30/2016	13	-1	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DOA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DOA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DOA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DOAの収益 ( 75.8% ) German市場 ( 5.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: DOAの収益 ( 75.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DOAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Soligenix 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘